Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that NeuroPace, Inc. made materially false and/or misleading statements and/or failed to disclose that: NeuroPace issued a press release on May 27, 2025, “announc[ing] the preliminary primary endpoint one-year results of the two-year NAUTILUS study evaluating safety and effectiveness of the RNS System for treatment of individuals with drug-resistant idiopathic generalized epilepsy (IGE).” The press release disclosed that “[t]he study did not reach statistical significance for the primary effectiveness endpoint in the overall study population, which was to show a longer time to a second generalized tonic-clonic seizure in the active stimulation group compared to the sham stimulation group.” Following this news, NeuroPace’s stock price fell over 28% on the same day.
In order to be eligible to join the NPCE class action lawsuit, you must have incurred a loss on shares of NeuroPace, Inc. purchased during the class period listed above.
TOP
